-
1
-
-
0031014450
-
Cancer statistics, 1997
-
Parker SL, Tong TT, Bolden S, et al: Cancer statistics, 1997 CA Cancer J Clin 41:5-27, 1997.
-
(1997)
CA Cancer J Clin
, vol.41
, pp. 5-27
-
-
Parker, S.L.1
Tong, T.T.2
Bolden, S.3
-
2
-
-
0018765410
-
Prostatic carcinoma
-
Klein LA: Prostatic carcinoma. N Engl J Med 300:824-833, 1979.
-
(1979)
N Engl J Med
, vol.300
, pp. 824-833
-
-
Klein, L.A.1
-
3
-
-
84928580276
-
Studies on prostatic cancer: 1. the effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges CV: Studies on prostatic cancer: 1. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
-
(1941)
Cancer Res
, vol.1
, pp. 293-297
-
-
Huggins, C.1
Hodges, C.V.2
-
4
-
-
0022345683
-
Randomized controlled study of orchiectomy vs long acting D-try-6-LHRH microcapsules in advanced proslatic carcinoma
-
Parmer H, Lightman SL, Allen L, et al: Randomized controlled study of orchiectomy vs long acting D-try-6-LHRH microcapsules in advanced proslatic carcinoma. Lancet 2:1201-1205, 1985.
-
(1985)
Lancet
, vol.2
, pp. 1201-1205
-
-
Parmer, H.1
Lightman, S.L.2
Allen, L.3
-
5
-
-
0024324367
-
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
-
Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989.
-
(1989)
N Engl J Med
, vol.321
, pp. 419-424
-
-
Crawford, E.D.1
Eisenberger, M.A.2
McLeod, D.G.3
-
6
-
-
0027457020
-
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
-
Janknegt RA, Abbou CC, Bartoletti R, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77-83, 1993.
-
(1993)
J Urol
, vol.149
, pp. 77-83
-
-
Janknegt, R.A.1
Abbou, C.C.2
Bartoletti, R.3
-
7
-
-
0028295588
-
Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer: A meta-analysis of seven randomized double-blinded trials 91056 patients
-
Bertagna C, DeGery A, Hucher M, et al: Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer: A meta-analysis of seven randomized double-blinded trials 91056 patients. Br J Urol 73:396-402, 1994.
-
(1994)
Br J Urol
, vol.73
, pp. 396-402
-
-
Bertagna, C.1
DeGery, A.2
Hucher, M.3
-
8
-
-
5944237302
-
Maximum androgen blockade in advance prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
-
Prostate Cancer Trialists Collaborative Group: Maximum androgen blockade in advance prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346265-269, 1995.
-
(1995)
Lancet
, vol.34
, pp. 6265-6269
-
-
-
9
-
-
5944226796
-
Meta analysis of published randomized clinical trials for MAB in prostate cancer
-
Caubet J-F, Tosteson TD, Dong W, et al: Meta analysis of published randomized clinical trials for MAB in prostate cancer (abstract 654) Proc Am Soc Clin Oncol 15-254, 1996.
-
(1996)
Proc am Soc Clin Oncol
, vol.15
, pp. 254
-
-
Caubet, J.-F.1
Tosteson, T.D.2
Dong, W.3
-
10
-
-
0019382176
-
Bilateral orchiectomy for carcinoma of prostate: Response of serum testosterone and clinical response to estrogen therapy
-
Klugo RC, Farah RN, Cerny JC: Bilateral orchiectomy for carcinoma of prostate: Response of serum testosterone and clinical response to estrogen therapy. Urology 17:49-50, 1981.
-
(1981)
Urology
, vol.17
, pp. 49-50
-
-
Klugo, R.C.1
Farah, R.N.2
Cerny, J.C.3
-
11
-
-
0000597499
-
Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases
-
Nesbit RM, Baum WC: Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases. JAMA 143:1317-1320, 1950.
-
(1950)
JAMA
, vol.143
, pp. 1317-1320
-
-
Nesbit, R.M.1
Baum, W.C.2
-
12
-
-
85004947039
-
Orchiectomy after presumed estrogen failure in the treatment of carcinoma of the prostate
-
Bjorn CL, Gray CP, Strauss E: Orchiectomy after presumed estrogen failure in the treatment of carcinoma of the prostate. West J Med 130:363-364, 1979.
-
(1979)
West J Med
, vol.130
, pp. 363-364
-
-
Bjorn, C.L.1
Gray, C.P.2
Strauss, E.3
-
13
-
-
0019478982
-
The response of metastatic adenocareinoma of the prostate 10 exogenous testosterone
-
Fowler JE, Whitmore WF: The response of metastatic adenocareinoma of the prostate 10 exogenous testosterone. J Urol 126:372-375, 1981.
-
(1981)
J Urol
, vol.126
, pp. 372-375
-
-
Fowler, J.E.1
Whitmore, W.F.2
-
14
-
-
0026021196
-
Response to orchiectomy following zoladex therapy for metastatic prostate carcinoma
-
Silver RI, Straus FH, Vogelzang NJ, et al: Response to orchiectomy following zoladex therapy for metastatic prostate carcinoma. Urology 37:17-21, 1991.
-
(1991)
Urology
, vol.37
, pp. 17-21
-
-
Silver, R.I.1
Straus, F.H.2
Vogelzang, N.J.3
-
15
-
-
0027944451
-
Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer. A Southwest Oncology Group Report
-
Hussain M, Wolf M, Marshall E, et al: Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer. A Southwest Oncology Group Report. J Clin Oncol 12:1868-1875, 1994.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1868-1875
-
-
Hussain, M.1
Wolf, M.2
Marshall, E.3
-
16
-
-
0027487289
-
Importance of continued testicular suppression in hormone refractory prostate cancer
-
Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormone refractory prostate cancer. J Clin Oncol 11:2167-2172, 1993.
-
(1993)
J Clin Oncol
, vol.11
, pp. 2167-2172
-
-
Taylor, C.D.1
Elson, P.2
Trump, D.L.3
-
17
-
-
0029011116
-
Mutation of the androgen receptor gene in meta static androgen-independent prostate cancer
-
Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen receptor gene in meta static androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995.
-
(1995)
N Engl J Med
, vol.332
, pp. 1393-1398
-
-
Taplin, M.E.1
Bubley, G.J.2
Shuster, T.D.3
-
18
-
-
0028838151
-
The in vitro response of four antisteroid receptor agents on the hormone responsive prostate cancer cell line LNCaP
-
Figg WD, McCall NA, Reed E, et al: The in vitro response of four antisteroid receptor agents on the hormone responsive prostate cancer cell line LNCaP. Oncology Reports 2:295-298, 1995.
-
(1995)
Oncology Reports
, vol.2
, pp. 295-298
-
-
Figg, W.D.1
McCall, N.A.2
Reed, E.3
-
19
-
-
0024351830
-
Aberrant response in vitro of hormone-responsive prostate cancer cells to anti-androgens
-
Wilding G, Chen M, Gelman EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to anti-androgens. Prostate 14:103-115, 1989.
-
(1989)
Prostate
, vol.14
, pp. 103-115
-
-
Wilding, G.1
Chen, M.2
Gelman, E.P.3
-
20
-
-
0029084601
-
The anti-androgen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients
-
Small EJ, Srinivas S: The anti-androgen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. Cancer 76:1428-1434, 1995.
-
(1995)
Cancer
, vol.76
, pp. 1428-1434
-
-
Small, E.J.1
Srinivas, S.2
-
21
-
-
0027203411
-
Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
-
Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1566-1572
-
-
Scher, H.I.1
Kelly, W.K.2
-
22
-
-
0028907804
-
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
-
Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-414, 1995.
-
(1995)
Am J Med
, vol.98
, pp. 412-414
-
-
Figg, W.D.1
Sartor, O.2
Cooper, M.R.3
-
23
-
-
0028256111
-
Prostate specific antigen decline after Casodex withdrawal: Evidence for an anti-androgen withdrawal syndrome
-
Small FJ, Carroll PR: Prostate specific antigen decline after Casodex withdrawal: Evidence for an anti-androgen withdrawal syndrome. Urology 43:408-410, 1994.
-
(1994)
Urology
, vol.43
, pp. 408-410
-
-
Small, F.J.1
Carroll, P.R.2
-
24
-
-
0343246680
-
A double-blind assessment of anti-androgen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer
-
Small EJ, Schellhammer P, Venner P, et al: A double-blind assessment of anti-androgen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer (abstract 658). Proc Am Soc Clin Oncol 15:255, 1996
-
(1996)
Proc am Soc Clin Oncol
, vol.15
, pp. 255
-
-
Small, E.J.1
Schellhammer, P.2
Venner, P.3
-
25
-
-
0029007052
-
Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the anti-androgen withdrawal syndrome
-
Dawson NA, McLeod DG: Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the anti-androgen withdrawal syndrome J Urol 153:1946-1947, 1995.
-
(1995)
J Urol
, vol.153
, pp. 1946-1947
-
-
Dawson, N.A.1
McLeod, D.G.2
-
26
-
-
5944251127
-
PSA response to megace withdrawal in hormone refractory prostate cancer (HRPC)
-
Wehbe TW, Wehbe P, Akerly III W, et al: PSA response to megace withdrawal in hormone refractory prostate cancer (HRPC) (abstract 667). Proc Am Soc Clin Oncol 15:257, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 257
-
-
Wehbe, T.W.1
Wehbe, P.2
Akerly III, W.3
-
27
-
-
0029619536
-
Hormone and antihormone withdrawal' Implications for the management of androgen-independent prostate cancer
-
Scher HI, Zhang ZF, Nanus D, et al: Hormone and antihormone withdrawal' Implications for the management of androgen-independent prostate cancer. Urology 47(suppl 1A):61-69, 1996.
-
(1996)
Urology
, vol.47
, Issue.SUPPL. 1A
, pp. 61-69
-
-
Scher, H.I.1
Zhang, Z.F.2
Nanus, D.3
-
28
-
-
0027249588
-
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy
-
Dupont A, Gomez JL, Cusan L, et al: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913, 1993.
-
(1993)
J Urol
, vol.150
, pp. 908-913
-
-
Dupont, A.1
Gomez, J.L.2
Cusan, L.3
-
29
-
-
0028089068
-
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in "hormonerefractory" prostate cancer
-
Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in "hormonerefractory" prostate cancer. J Natl Cancer Inst 86:222-227, 1994.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 222-227
-
-
Sartor, O.1
Cooper, M.2
Weinberger, M.3
-
30
-
-
0029982140
-
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone-refractory prostate cancer
-
Figg WD, Dawson NA, Middleman MN et al. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone-refractory prostate cancer. Acta Oncol 35:763-765, 1996.
-
(1996)
Acta Oncol
, vol.35
, pp. 763-765
-
-
Figg, W.D.1
Dawson, N.A.2
Middleman, M.N.3
-
31
-
-
0038417687
-
High dose casodex for prostate cancer: PSA decline in patients with flutamide withdrawal responses
-
Liebertz C, Kelly WK, Theodoulou M et al: High dose casodex for prostate cancer: PSA decline in patients with flutamide withdrawal responses (abstract 603). Proc Am Soc Clin Oncol 14:232, 1995
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
, pp. 232
-
-
Liebertz, C.1
Kelly, W.K.2
Theodoulou, M.3
-
32
-
-
0343682326
-
Bicalutamide for androgen-independent prostate cancer
-
Fenton MA, Rode P, Constatine M et al: Bicalutamide for androgen-independent prostate cancer (abstract 684) Proc Am Soc Clin Oncol 15:262, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 262
-
-
Fenton, M.A.1
Rode, P.2
Constatine, M.3
-
33
-
-
0002575776
-
Phase II mal of Casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: A SWOG Study (SWOG 9235)
-
Kucuk O, Blumenstein, Moinponr C, et al: Phase II mal of Casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: A SWOG Study (SWOG 9235) (abstract 618) Proc Am Soc Clin Oncol 15:245, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 245
-
-
Kucuk, O.1
Blumenstein2
Moinponr, C.3
-
34
-
-
0001170653
-
Megestrol acetate in men with hormone-refractory prostate cancer: Prostate specific antigen response and anti-androgen withdrawal: CALGB 9181
-
Dawson NA, Small EJ, Conaway M, et al: Megestrol acetate in men with hormone-refractory prostate cancer: Prostate specific antigen response and anti-androgen withdrawal: CALGB 9181 (abstract 601). Proc Am Soc Clin Oncol 15:241, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 241
-
-
Dawson, N.A.1
Small, E.J.2
Conaway, M.3
-
35
-
-
0343846842
-
Significant activity by high dose tamoxifen in hormone refractory prostate cancer
-
Bergan RC, Blagosklonny M, Dawson NA, et al: Significant activity by high dose tamoxifen in hormone refractory prostate cancer (abstract 637). Proc Am Soc Clin Oncol 14:241, 1995.
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
, pp. 241
-
-
Bergan, R.C.1
Blagosklonny, M.2
Dawson, N.A.3
-
36
-
-
0024389842
-
High-dose ketoconazole in advance hormone-refractory prostate cancer. Endocrinologic and clinical effects
-
Trump DL, Havlin KH, Messing EM, et al High-dose ketoconazole in advance hormone-refractory prostate cancer. Endocrinologic and clinical effects. J Clin Oncol 7:1093-1098, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1093-1098
-
-
Trump, D.L.1
Havlin, K.H.2
Messing, E.M.3
-
37
-
-
0030999075
-
Keto conazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
-
Small EJ, Egan B, Apodaca D, et al: Keto conazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 4(5): 1204-1207, 1997.
-
(1997)
J Urol
, vol.4
, Issue.5
, pp. 1204-1207
-
-
Small, E.J.1
Egan, B.2
Apodaca, D.3
-
38
-
-
0000855450
-
Cortisone treatment in advance carcinoma of the prostate
-
Miller CM, Hinman F: Cortisone treatment in advance carcinoma of the prostate. J Urol 72:485-496, 1954.
-
(1954)
J Urol
, vol.72
, pp. 485-496
-
-
Miller, C.M.1
Hinman, F.2
-
39
-
-
0024535895
-
Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response
-
Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 590-597
-
-
Tannock, I.1
Gospodarowicz, M.2
Meakin, W.3
-
40
-
-
0026625134
-
Suramin and prostate cancer: The role of hydrocortisone
-
Harland SJ, Duchesne GM: Suramin and prostate cancer: The role of hydrocortisone (letter) Eur J Cancer 28A:1295, 1992.
-
(1992)
Eur J Cancer
, vol.28 A
, pp. 1295
-
-
Harland, S.J.1
Duchesne, G.M.2
-
41
-
-
85004984992
-
Prostate specific antigen levels and clinical response to low-dose dexamethasone for hormone refractory metastatic prostate cancer
-
Storlie JA, Buckner JC, Wiseman GA, et al: Prostate specific antigen levels and clinical response to low-dose dexamethasone for hormone refractory metastatic prostate cancer (abstract 726). Proc Am Soc Clin Oncol 13:235, 1994.
-
(1994)
Proc Am Soc Clin Oncol
, vol.13
, pp. 235
-
-
Storlie, J.A.1
Buckner, J.C.2
Wiseman, G.A.3
-
42
-
-
0024464395
-
Estramustine-A nitrogen mustard/steroid with antimicrotubule activity
-
Tew KD, Stearns, ME: Estramustine-A nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther 43:299-319, 1989.
-
(1989)
Pharmacol Ther
, vol.43
, pp. 299-319
-
-
Tew, K.D.1
Stearns, M.E.2
-
43
-
-
84966070158
-
Role of estramustine phosphate in the treatment of prostate cancer
-
Schaefers H (ed). Utrecht
-
Benson RC: Role of estramustine phosphate in the treatment of prostate cancer, in Schaefers H (ed). Estracyst, Scientific Edition 2, pp 35-64. Utrecht, 1988.
-
(1988)
Estracyst, Scientific Edition 2
, pp. 35-64
-
-
Benson, R.C.1
-
44
-
-
0027486654
-
Taxol in advanced, hormone-refractory carcinoma of the prostate
-
Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone-refractory carcinoma of the prostate. Cancer 72:2457-2460, 1993.
-
(1993)
Cancer
, vol.72
, pp. 2457-2460
-
-
Roth, B.J.1
Yeap, B.Y.2
Wilding, G.3
-
45
-
-
0028226103
-
Oral etoposide in the treatment of hormone refractory prostate cancer
-
Hussain M, Pienta KJ, Redman BG, et al: Oral etoposide in the treatment of hormone refractory prostate cancer Cancer 74:100-103, 1994.
-
(1994)
Cancer
, vol.74
, pp. 100-103
-
-
Hussain, M.1
Pienta, K.J.2
Redman, B.G.3
-
46
-
-
0027154852
-
Inhibition of prostate cancer growth by estranmstine and etoposide: Evidence for interactions at the nuclear matrix
-
Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estranmstine and etoposide: Evidence for interactions at the nuclear matrix. J Urol 149:1622-1625, 1993.
-
(1993)
J Urol
, vol.149
, pp. 1622-1625
-
-
Pienta, K.J.1
Lehr, J.E.2
-
47
-
-
0023952134
-
Anti invasive activity of estramustine on malignant MO4 cells and DU-145 human prostate carcinoma cells in vitro
-
Mareel MM, Storme GA, Dragonett CH, et al: Anti invasive activity of estramustine on malignant MO4 cells and DU-145 human prostate carcinoma cells in vitro. Cancer Res 48:1842-1849, 1988.
-
(1988)
Cancer Res
, vol.48
, pp. 1842-1849
-
-
Mareel, M.M.1
Storme, G.A.2
Dragonett, C.H.3
-
48
-
-
0026808448
-
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines
-
Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992.
-
(1992)
Cancer Res
, vol.52
, pp. 4433-4440
-
-
Speicher, L.A.1
Barone, L.2
Tew, K.D.3
-
49
-
-
0028104733
-
Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate
-
Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2005-2012
-
-
Pienta, K.J.1
Redman, B.2
Hussain, M.3
-
50
-
-
1542532447
-
Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: Activity in hormone-refractory disease (HRPC)
-
Hudes G, Nathan F, Chapman A, et al: Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: Activity in hormone-refractory disease (HRPC) (abstract 622). Proc Am Soc Clin Oncol 14:237, 1995.
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
, pp. 237
-
-
Hudes, G.1
Nathan, F.2
Chapman, A.3
-
51
-
-
0027097763
-
Phase II study of estramustine and vmblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
-
Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vmblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1754-1761
-
-
Hudes, G.R.1
Greenberg, R.2
Krigel, R.L.3
-
52
-
-
0007875652
-
A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer
-
Reese D, Burris H, Bellegrun A, et al: A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (abstract 673). Proc Am Soc Clin Oncol 15:259, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 259
-
-
Reese, D.1
Burris, H.2
Bellegrun, A.3
-
53
-
-
0003965169
-
Report of an extended phase II trial of oral estramustine and oral etoposide in the treatment of hormone refractory prostate cancer patients
-
Pienta KJ, Flaherty E, Hussain M, et al: Report of an extended phase II trial of oral estramustine and oral etoposide in the treatment of hormone refractory prostate cancer patients (abstract 681). Proc Am Soc Oncol 15:261, 1996.
-
(1996)
Proc Am Soc Oncol
, vol.15
, pp. 261
-
-
Pienta, K.J.1
Flaherty, E.2
Hussain, M.3
-
54
-
-
5944238998
-
Preliminary results of estramustine and vinblastine as primary treatment for metastatic prostatic cancer
-
Trudeau M, Aronson S, Bazinet M: Preliminary results of estramustine and vinblastine as primary treatment for metastatic prostatic cancer (abstract 662). Proc Am Soc Clin Oncol 15:256, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 256
-
-
Trudeau, M.1
Aronson, S.2
Bazinet, M.3
-
55
-
-
5944251250
-
Strontium-89, estramustine, and vinblastine in hormone refractory prostate carcinoma: Concurrent chemoradiotherapy
-
Wehbe T, Akerley W, Sloan L, et al. Strontium-89, estramustine, and vinblastine in hormone refractory prostate carcinoma: Concurrent chemoradiotherapy (abstract 682). Proc Am Soc Clin Oncol 15:261, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 261
-
-
Wehbe, T.1
Akerley, W.2
Sloan, L.3
-
56
-
-
0027511899
-
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory proslate cancer
-
Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory proslate cancer. J Clin Oncol 11:607-615, 1993.
-
(1993)
J Clin Oncol
, vol.11
, pp. 607-615
-
-
Kelly, W.K.1
Scher, H.I.2
Mazumdar, M.3
-
57
-
-
0027504768
-
Oral cyclophosphamide for the management of hormone-refractory prostate cancer
-
Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer Br J Urol 72:625-628, 1993
-
(1993)
Br J Urol
, vol.72
, pp. 625-628
-
-
Raghavan, D.1
Cox, K.2
Pearson, B.S.3
-
58
-
-
0029923406
-
Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer
-
Small EJ, Srinivas S, Egan B, et al Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 14:1617-1625, 1996.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1617-1625
-
-
Small, E.J.1
Srinivas, S.2
Egan, B.3
-
59
-
-
0024535895
-
Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response
-
Tannock T, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 590-597
-
-
Tannock, T.1
Gospodarowicz, M.2
Meakin, W.3
-
60
-
-
0028208515
-
Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
-
Moore MJ, Osoba D, Murphy K, et al: Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689-694, 1994
-
(1994)
J Clin Oncol
, vol.12
, pp. 689-694
-
-
Moore, M.J.1
Osoba, D.2
Murphy, K.3
-
61
-
-
8944220720
-
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate, cancer: A Canadian randomized trial with palliative endpoints
-
Tannock IF, Osoba D, Stockler MR, et al Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate, cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756-1764, 1996.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1756-1764
-
-
Tannock, I.F.1
Osoba, D.2
Stockler, M.R.3
-
62
-
-
0343363359
-
Hydrocortisone with and without mitoxantrone in patients with hormone-refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B (9182) comparing chemotherapy to best supportive care
-
Kantoff PW, Conaway M, Winer E, et al: Hydrocortisone with and without mitoxantrone in patients with hormone-refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B (9182) comparing chemotherapy to best supportive care (abstract 2013). Proc Am Soc Clin Oncol 14:1748, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.14
, pp. 1748
-
-
Kantoff, P.W.1
Conaway, M.2
Winer, E.3
-
63
-
-
0027270333
-
The treatment of painful osseous metastases with phosphorus-32-labeled phosphates
-
Silberstein EB: The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 20, No.3 2(suppl):10-21, 1993.
-
(1993)
Semin Oncol
, vol.20
, Issue.32 SUPPL.
, pp. 10-21
-
-
Silberstein, E.B.1
-
64
-
-
0028598194
-
The use of strontium-89 for palliation of pain form bone metastases associated with hormone-refractory prostate cancer
-
Crawford ED, Kozlowski JM, Debruyne FMI, et al: The use of strontium-89 for palliation of pain form bone metastases associated with hormone-refractory prostate cancer. Urology 44:481-485, 1994.
-
(1994)
Urology
, vol.44
, pp. 481-485
-
-
Crawford, E.D.1
Kozlowski, J.M.2
Debruyne, F.M.I.3
-
65
-
-
0027252452
-
Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
-
Porter AT, McEwan AJB, Powe JE, et al Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993.
-
(1993)
Int J Radiat Oncol Biol Phys
, vol.25
, pp. 805-813
-
-
Porter, A.T.1
McEwan, A.J.B.2
Powe, J.E.3
-
66
-
-
0028233520
-
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
-
Quilty PM, Kirk D, Bolger JJ, et al: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33-40, 1994.
-
(1994)
Radiother Oncol
, vol.31
, pp. 33-40
-
-
Quilty, P.M.1
Kirk, D.2
Bolger, J.J.3
-
67
-
-
0026750068
-
Samarium-153-EDTMP: Pharmacokinetic toxicity and pain response using an escalating dose schedule in treatment of metastalic bone cancer
-
Farhanght M, Holmes RA, Volkert WA, et al: Samarium-153-EDTMP: Pharmacokinetic toxicity and pain response using an escalating dose schedule in treatment of metastalic bone cancer J Nucl Med 33:1451-1458, 1992.
-
(1992)
J Nucl Med
, vol.33
, pp. 1451-1458
-
-
Farhanght, M.1
Holmes, R.A.2
Volkert, W.A.3
-
68
-
-
0027521907
-
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial
-
Collins C, Eary JF, Donaldson G, et al: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 34:1839-1844, 1993.
-
(1993)
J Nucl Med
, vol.34
, pp. 1839-1844
-
-
Collins, C.1
Eary, J.F.2
Donaldson, G.3
-
69
-
-
0027958545
-
Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases
-
Bayouth JE, Macey DJ, Kasi LP, et al: Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 35:63-69, 1994.
-
(1994)
J Nucl Med
, vol.35
, pp. 63-69
-
-
Bayouth, J.E.1
Macey, D.J.2
Kasi, L.P.3
-
70
-
-
5944244811
-
Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma
-
Quick D, Reid R, Hoskin P, et al: Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma (abstract 1654). Proc Am Soc Clin Oncol 15.514, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 514
-
-
Quick, D.1
Reid, R.2
Hoskin, P.3
-
71
-
-
0026444214
-
Rhenium-186 hydroxyethylidene Diphosphonate for the treatment of painful osseous metastases
-
Maxon HR, Thomas, SR, Hertzberg VS, et al: Rhenium-186 hydroxyethylidene Diphosphonate for the treatment of painful osseous metastases. Seinin Nucl Med 23:33-40, 1992
-
(1992)
Seinin Nucl Med
, vol.23
, pp. 33-40
-
-
Maxon, H.R.1
Thomas, S.R.2
Hertzberg, V.S.3
-
72
-
-
5944232832
-
Radiopharmaceutical therapy of cancer pain from bone metastases
-
Somerset, New Jersey, Wiley-Liss
-
Silberstein EB: Radiopharmaceutical therapy of cancer pain from bone metastases, in Prostate Cancer pp 261-268. Somerset, New Jersey, Wiley-Liss, 1994.
-
(1994)
Prostate Cancer
, pp. 261-268
-
-
Silberstein, E.B.1
-
73
-
-
0022393635
-
Generalized increase in bone resorption in carcinomaof the prostate
-
Urwin GH, Percival RC, Harris S, et al: Generalized increase in bone resorption in carcinomaof the prostate. Br J Urol 57:721-723, 1985.
-
(1985)
Br J Urol
, vol.57
, pp. 721-723
-
-
Urwin, G.H.1
Percival, R.C.2
Harris, S.3
-
74
-
-
5944227885
-
Effects of disodium pamidronate in metastatic prostate cancer
-
Clarke NW, McClure J, George NJR: Effects of disodium pamidronate in metastatic prostate cancer (abstract). Eur J Cancer 27(suppl 2):117, 1991.
-
(1991)
Eur J Cancer
, vol.27
, Issue.2 SUPPL.
, pp. 117
-
-
Clarke, N.W.1
McClure, J.2
George, N.J.R.3
-
75
-
-
0017831729
-
Suramin: With special reference to onchocerciasis
-
Hawkins F: Suramin: With special reference to onchocerciasis. Adv Pharmacol Chemother 15-289-322, 1978.
-
(1978)
Adv Pharmacol Chemother
, vol.15
, pp. 289-322
-
-
Hawkins, F.1
-
76
-
-
0024593227
-
Suramin: An anticancer drug with a unique mechanism of action
-
Stem CA, La Rocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 499-508
-
-
Stem, C.A.1
La Rocca, R.V.2
Thomas, R.3
-
77
-
-
0026740863
-
Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
-
Myers C, Cooper M, Stein CA, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10:881-889, 1992.
-
(1992)
J Clin Oncol
, vol.10
, pp. 881-889
-
-
Myers, C.1
Cooper, M.2
Stein, C.A.3
-
78
-
-
0029127207
-
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer
-
Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2174-2186
-
-
Eisenberger, M.A.1
Sinibaldi, V.J.2
Reyno, L.M.3
-
79
-
-
0029078689
-
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
-
Dawson NA, Cooper MR, Figg WD, et al: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:453-462, 1995.
-
(1995)
Cancer
, vol.76
, pp. 453-462
-
-
Dawson, N.A.1
Cooper, M.R.2
Figg, W.D.3
-
80
-
-
0029101785
-
Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
-
Kelly WK, Curley T, Leibertz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208-2213, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2208-2213
-
-
Kelly, W.K.1
Curley, T.2
Leibertz, C.3
-
81
-
-
0029120380
-
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin
-
Bitton RJ, Figg WD, Venzon DJ, et al: Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 13:2223-2229, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2223-2229
-
-
Bitton, R.J.1
Figg, W.D.2
Venzon, D.J.3
-
83
-
-
0029120379
-
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer
-
Kobayashi K, Vokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1996
-
(1996)
J Clin Oncol
, vol.13
, pp. 2196-2207
-
-
Kobayashi, K.1
Vokes, E.E.2
Vogelzang, N.J.3
-
84
-
-
0029827498
-
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response
-
Bowden CJ, Figg WD, Dawson NA, et al: A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response. Cancer Chemother Pharmacol (39)1-2:1-8, 1996.
-
(1996)
Cancer Chemother Pharmacol
, vol.1-2
, Issue.39
, pp. 1-8
-
-
Bowden, C.J.1
Figg, W.D.2
Dawson, N.A.3
-
86
-
-
0027180685
-
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacologic concentrations of phenylacetate
-
Samid D, Shack S, Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacologic concentrations of phenylacetate. J Clin Invest 91(5):22W-2295, 1993.
-
(1993)
J Clin Invest
, vol.91
, Issue.5
-
-
Samid, D.1
Shack, S.2
Myers, C.E.3
-
87
-
-
5944227884
-
Phenylacetate induces the production of prostate specific antigen in prostate cancer cells: In vitro and in vivo studies
-
Walls RG, Thibault A, Wood C, et al: Phenylacetate induces the production of prostate specific antigen in prostate cancer cells: In vitro and in vivo studies (abstract 46). Proc Am Soc Clin Oncol 14:86, 1995.
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
, pp. 86
-
-
Walls, R.G.1
Thibault, A.2
Wood, C.3
-
88
-
-
0142124545
-
Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate
-
Bowling MK, Nelson JB, Tong KP, et al: Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (abstract 43). Proc Am Soc Clin Oncol 15:94, 1996
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 94
-
-
Bowling, M.K.1
Nelson, J.B.2
Tong, K.P.3
-
89
-
-
0029396721
-
Phase I/II dose-escalation study of liazorole in patients with stage D. hormone-refractory carcinoma of the prostate
-
Seidmon EJ, Trump DL, Kreis, W, et al: Phase I/II dose-escalation study of liazorole in patients with stage D. hormone-refractory carcinoma of the prostate Ann Surg Oncol 2(6) 550-556, 1995
-
(1995)
Ann Surg Oncol
, vol.2
, Issue.6
, pp. 550-556
-
-
Seidmon, E.J.1
Trump, D.L.2
Kreis, W.3
-
90
-
-
5944257998
-
Effects of liazorole on PSA levels in patients with relapsed stage D prostate cancer
-
Smith J, Andriole G, Ahmann F, et al: Effects of liazorole on PSA levels in patients with relapsed stage D prostate cancer (abstract 636). Proc Am Soc Clin Oncol 15:250, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 250
-
-
Smith, J.1
Andriole, G.2
Ahmann, F.3
-
91
-
-
0025006735
-
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer
-
Smith PH, Bono A, da Silva C, et al: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer 66.1009-1016, 1990.
-
(1990)
Cancer
, vol.66
, pp. 1009-1016
-
-
Smith, P.H.1
Bono, A.2
Da Silva, C.3
-
92
-
-
0021358371
-
The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer
-
Pollen JJ, Witztum KF, Ashburn WL: The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer. Am J Roentgenol 142:773-776, 1984.
-
(1984)
Am J Roentgenol
, vol.142
, pp. 773-776
-
-
Pollen, J.J.1
Witztum, K.F.2
Ashburn, W.L.3
-
93
-
-
5944255278
-
Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer
-
in press
-
Smith DC, Dunn RL, Strawderman MS, et al: Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer. J Clin Oncol, 1997 (in press).
-
(1997)
J Clin Oncol
-
-
Smith, D.C.1
Dunn, R.L.2
Strawderman, M.S.3
-
94
-
-
5944235085
-
Eligibility and response criteria in hormone refractory prostate cancer (PMPC): A need for consensus
-
Dawson NA, Eligibility and response criteria in hormone refractory prostate cancer (PMPC): A need for consensus (abstract 1129). Proc Am Soc Clin Oncol 16:317A, 1997.
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Dawson, N.A.1
-
95
-
-
0343825245
-
Post-therapy changes in biochemical markers in patients with androgen independent prostate cancer
-
Kelly WK, Steineck G, Mazumdar M, et al: Post-therapy changes in biochemical markers in patients with androgen independent prostate cancer (abstract 606). Proc Am Soc Clin Oncol 14:233, 1995.
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
, pp. 233
-
-
Kelly, W.K.1
Steineck, G.2
Mazumdar, M.3
|